Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome : vimarsana.com

– Tolerability profile observed supports continued development in Cohort 2, with no treatment attributed serious adverse events –


– Reduction in incidences of microbiome pathogen... | May 9, 2023

Related Keywords

United States , American , Matthew Henn , International Blood , Nasdaq , American Health Drug , Marrow Transplant Research , Exchange Commission , Health Science , Seres Therapeutics Inc , Seres Therapeutics , Chief Medical Officer , Study Design , Chief Scientific Officer , Hematologic Malignancies , Memorial Sloan Kettering Cancer Center , Infection Protection , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Allogeneic Hematopoietic Cell , Intestinal Domination , Clinical Infectious , Hematopoietic Stem Cell Transplantation , American Health , Nc Stock Exchange , Ews , Nformation , Ress Release , Olerability , Rofile , Bserved , Upports , Ontinued , Evelopment , N , Ohort , Ith , O , Reatment , Ttributed , Erious , Dverse , Vents , Eduction , Ncidences , F , Icrobiome Mcrb Us81750r1023 ,